Ocugen, Inc. (OCGN)
| Market Cap | 487.46M +142.8% |
| Revenue (ttm) | 4.47M -1.3% |
| Net Income | -71.67M |
| EPS | -0.24 |
| Shares Out | 338.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,151,941 |
| Open | 1.460 |
| Previous Close | 1.455 |
| Day's Range | 1.380 - 1.510 |
| 52-Week Range | 0.640 - 2.725 |
| Beta | 2.31 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+577.08%) |
| Earnings Date | May 5, 2026 |
About OCGN
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ... [Read more]
Financial Performance
In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 577.08% from the latest price.
News
Ocugen reports Q1 EPS (6c), consensus (5c)
Reports Q1 revenue $1.53M, consensus $358,140. “In the first few months of 2026, we have completed enrollment of two of our late-stage programs and are diligently working toward initiating our
Ocugen Provides Business Update with First Quarter 2026 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p 30% reductio...
Ocugen Earnings Call Transcript: Q1 2026
Advanced three late-stage gene therapy programs with strong clinical progress and positive phase II data in GA. Cash runway extended into 2028 following a $115M convertible notes offering, supporting pivotal trials and planned BLA submissions for RP, Stargardt, and GA.
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 ...
Ocugen announces private offering of $115M of convertible senior notes
Ocugen (OCGN) announced its intention to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its ...
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that i...
Ocugen to Present at April 2026 Investor and Industry Conferences
MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that D...
Ocugen completes dosing in GARDian3 trial
Ocugen (OCGN) announced that dosing has been successfully completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial for OCU410ST-a modifier gene therapy candidate devel...
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
MALVERN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that d...
Ocugen price target raised to $12 from $8 at Noble Capital
Noble Capital raised the firm’s price target on Ocugen (OCGN) to $12 from $8 and keeps an Outperform rating on the shares after the company reported Phase 2 data for
Ocugen price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Ocugen (OCGN) to $10 from $7 and keeps a Buy rating on the shares. The firm cites the Phase
Ocugen Transcript: Study update
Phase II results for OCU410 in GA showed a 31% reduction in lesion growth at 12 months with a favorable safety profile and significant preservation of photoreceptor structure. The medium dose will advance to phase III, targeting a global enrollment of 300 patients.
Ocugen announces 12-month data from ArMaDa clinical trial of OCU410
Ocugen (OCGN) announced 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration. Key ...
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positi...
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced th...
Ocugen initiated with a Buy at Canaccord
Canaccord initiated coverage of Ocugen (OCGN) with a Buy rating and $12 price target The company has three clinical stage programs in rare and non-rare retinal diseases, the analyst tells
Ocugen initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Ocugen (OCGN) with an Outperform rating and $10 price target The firm views Ocugen as an emerging gene therapy leader in blinding ocular disorders. The company’s
Ocugen price target raised to $22 from $15 at Lucid Capital
Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary
Ocugen Earnings Call Transcript: Q4 2025
Significant clinical and operational progress was made across gene therapy programs, with key trials advancing and positive data reported. Financial position was strengthened through fundraising and licensing, supporting a cash runway into late 2026 or beyond.
Ocugen reports Q4 EPS (6c), consensus (6c)
“Considerable development across all our modifier gene therapy programs, notable licensing and financing agreements to strengthen our financial position, and meaningful appointments to our leadership ...
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected ...
Options Volatility and Implied Earnings Moves Today, March 04, 2026
Today, several major companies are expected to report earnings: Microvision (MVIS), Veeva Systems (VEEV), Wix (WIX), Ocugen (OCGN), Okta (OKTA), Sea (SE), ChargePoint Holdings (CHPT), Stem Inc (STEM),...
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete
Ocugen (OCGN) announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa. As a one-year clinical trial, topline data will be available in
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
MALVERN, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that e...